CN105287409A - Medicinal meclofenoxate hydrochloride composition freeze-dried powder injection for treating senile dementia - Google Patents
Medicinal meclofenoxate hydrochloride composition freeze-dried powder injection for treating senile dementia Download PDFInfo
- Publication number
- CN105287409A CN105287409A CN201510860105.9A CN201510860105A CN105287409A CN 105287409 A CN105287409 A CN 105287409A CN 201510860105 A CN201510860105 A CN 201510860105A CN 105287409 A CN105287409 A CN 105287409A
- Authority
- CN
- China
- Prior art keywords
- meclofenoxate hydrochloride
- dried powder
- meclofenoxate
- freeze
- senile dementia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention belongs to the technical field of medicine, and relates to a medicinal meclofenoxate hydrochloride composition freeze-dried powder injection for treating senile dementia. The medicinal meclofenoxate hydrochloride composition freeze-dried powder injection for treating senile dementia comprises meclofenoxate hydrochloride and an excipient. The excipient is trehalose, the meclofenoxate hydrochloride is a novel crystal complex, and an X-ray powder diffraction pattern measured by adopting Cu-Ka rays is shown as Figure 1. The novel crystal structure of the meclofenoxate hydrochloride is different from the prior art, the experimental verification shows that compared with the prior art, the moisture absorption performance and mobility of the meclofenoxate hydrochloride crystal complex are obviously improved, the content of moisture and impurities is relatively low, the stability is better, and convenience is brought to the preparation of a formulation; the bioavailability is higher, and the adverse reaction is reduced. Compared with the prior art, the freeze-dried powder injection prepared by using the meclofenoxate hydrochloride crystal complex is good in stability, extremely low in moisture and impurity content, low in adverse reaction, good in stability after being compounded with solvent, extremely low in content of insoluble micro-particles and very suitable for the clinical application.
Description
Technical field
The present invention relates to a kind of medicine meclofenoxate hydrochloride composite freeze-dried powder agent for the treatment of senile dementia, belong to medical art.
Background technology
The chemistry of meclofenoxate hydrochloride is called 2-(dimethylamino) ethyl parachlorophen-oxyacetic acid ester hydrochloride, a kind of central nervous system stimulant and cranial nerve nutrient drug, central nervous system function can be improved, comprise and cause awakening, inspire enthusiasm, excited breathing, improve neural reflex and increase freely activity, it can promote protein assimilation, can be used as the raw material of synthesis choline and acetylcholine in vivo, and then synthesis lecithin, thus change central nervous system nerve mediator content, acetylcholine amount in brain is increased, there is oxygen lack resistant function, promote the redox reaction of brain cell, promote brain energy metabolism, improve study, memory and cognition function, improve cerebral hemodynamic, promote the recovery of Clinical symptom and sign.
The indication of the meclofenoxate hydrochloride preparation of current domestic listing be clinically be used for traumatic stupor, anoxia neonatorum disease, children's send urine disease, disturbance of consciousness, mentally deranged, senile psychosis, senile dementia and alcoholism, carbon monoxide poisoning etc.
Meclofenoxate hydrochloride less stable, and because containing ester bond in molecule, aqueous solution is unstable, facile hydrolysis.Aqueous solution pH raises, and hydrolysis rate is accelerated.In order to address this problem, prior art generally attempts from preparation aspect addressing this problem, the means of use for add adjuvant and adopt comparatively complicated technology to overcome its unstability.Although but the stability that prior art improves meclofenoxate hydrochloride in preparation has certain effect needs to add more adjuvant and needs coordinate the technique of comparatively complexity, but although there is certain effect limited use, limit the application of meclofenoxate hydrochloride, because facile hydrolysis meclofenoxate hydrochloride is unstable in feed stage, need high preservation condition.The prior art also had attempts the meclofenoxate hydrochloride obtaining higher stability from change crystal formation, as: China application CN103214382B, the Meclofenoxate hydrochloride compound that this application provides and drug regimen thereof are compared with prior art, there is better storage stability and mobility, the present inventor finds in test, although the meclofenoxate hydrochloride obtained in this application has good stability under room temperature and acceleration environment, but less stable in the factorial experiments of other influences drug quality, especially still have higher draw moist, make the easy water of hydroscopicity solution of meclofenoxate hydrochloride.China application CN103396328B, this application inventor obtains a kind of Meclofenoxate hydrochloride compound of crystal form unexpectedly in long-term a large amount of research process, and this compound draws moist very low, not easily water of hydroscopicity solution and have high quality stability.The present invention also provides effective ingredient to be composite preparation of Meclofenoxate hydrochloride compound of the present invention and preparation method thereof, according to the preparation that content of the present invention can be prepared into, keep high stability, obviously be better than commercially available kind, substantially increase the safety of meclofenoxate hydrochloride use, effectiveness, but its bioavailability is lower, and rate of side effects is higher.
The present inventor starts with from the research of meclofenoxate hydrochloride solid chemical material existence, has prepared a kind of new meclofenoxate hydrochloride crystalline compounds through a large amount of tests.Meclofenoxate hydrochloride crystal-form compound provided by the present invention compared with prior art hygroscopicity, mobility is significantly improved, and moisture and impurity content are extremely low, and stability is better, and the preparation for preparation provides conveniently.Meclofenoxate hydrochloride crystalline compounds provided by the invention compared with prior art has higher bioavailability, and side reaction rate reduces.Utilize the lyophilized injectable powder that this crystal compound is obtained, be compared with the prior art, good stability, moisture and impurity content are extremely low, and side reaction rate is low, and good with solvent compatibility rear stability, particulate matter content is extremely low, is very suitable for clinical practice.
Summary of the invention
The object of the present invention is to provide a kind of medicine meclofenoxate hydrochloride composite freeze-dried powder agent for the treatment of senile dementia.
In order to complete object of the present invention, the technical scheme of employing is:
The present invention relates to a kind of medicine meclofenoxate hydrochloride composite freeze-dried powder agent for the treatment of senile dementia, comprise meclofenoxate hydrochloride and excipient, described meclofenoxate hydrochloride is crystal, and the X-ray powder diffraction pattern that the measurement of use Cu-K alpha ray obtains as shown in Figure 1.
As preferably, with parts by weight, the medicine meclofenoxate hydrochloride compositions of described treatment senile dementia is made up of the meclofenoxate hydrochloride of 3 weight portions, the excipient of 8-10 weight portion.
As preferably, with parts by weight, the medicine meclofenoxate hydrochloride compositions of described treatment senile dementia is made up of the meclofenoxate hydrochloride of 3 weight portions, the excipient of 9 weight portions.
As preferably, the preparation method of the medicine meclofenoxate hydrochloride composite freeze-dried powder agent of described treatment senile dementia comprises the following steps: get Meclofenoxate hydrochloride compound of the present invention, inject and blunge, add the excipient of recipe quantity, adjust ph, then be stirred to pH constant after, mend and inject water to 100 times that liquor capacity is meclofenoxate hydrochloride weight, then active carbon coarse filtration is used, successively through 1.0 μm, 0.45 μm, the microporous filter membrane aseptic filtration of 0.22 μm, filter into sterilizing room, measure pH and content qualified after, fill, pressure half plug, put into the freeze drying box being cooled to-25 DEG C, frozen drying, tamponade outlet, roll lid.
As preferably, described excipient is trehalose.
As preferably, described lyophilization is:
Pre-freeze: by point medicinal liquid installed in-25 DEG C of insulation lyophilizing 5 hours;
Distillation: medicinal liquid good for pre-freeze is carried out evacuation ,-20 DEG C are incubated lyophilizing 15 hours;
Dry: the sample after distillation being terminated is warming up to 35 DEG C, heat preservation and dryness 3 hours.
As preferably, described adjustment pH is 4.0-5.0.
The preparation method of the meclofenoxate hydrochloride crystal that the present invention treats in the medicine meclofenoxate hydrochloride compositions of senile dementia comprises the following steps:
(1) ground by meclofenoxate hydrochloride crude product, cross 80 mesh sieves, then joining volume is in the deionized water of 6 times of meclofenoxate hydrochloride weight, and 130 revs/min are stirred 10 minutes;
Add the dichloroethanes that volume is 4 times of meclofenoxate hydrochloride weight under (2) 90 revs/min of stirrings, be warming up to 35 DEG C simultaneously;
(3) after solution adds, leave standstill 3 hours, the volume dripping 0 DEG C under 150 revs/min of conditions stirred is 8 times of ether of meclofenoxate hydrochloride weight, the mixed solution of carbon tetrachloride, and the volume ratio of ether, carbon tetrachloride is 3:2, at the uniform velocity dropwises in 2 hours;
(4) be cooled to-5 DEG C after being added dropwise to complete, continue stirring 2 hours under the stir speed (S.S.) of 110 revs/min, leave standstill 1 hour crystallize out, filter, washing, vacuum drying obtains meclofenoxate hydrochloride crystal.
Below technical scheme of the present invention is made further explanation:
The present invention is by the precise controlling to crystallization condition, and prepared a kind of meclofenoxate hydrochloride novel crystal forms unlike the prior art, the X-ray powder diffraction pattern of this meclofenoxate hydrochloride crystal unlike the prior art.Simultaneously due to the ins and outs of this crystal formation, find through test, meclofenoxate hydrochloride crystalline compounds provided by the invention compared with prior art has higher bioavailability, and side reaction rate reduces.Utilize the lyophilized injectable powder that this crystal compound is obtained, be compared with the prior art, good stability, moisture and impurity content are extremely low, and side reaction rate is low, and good with solvent compatibility rear stability, particulate matter content is extremely low, is very suitable for clinical practice.
Accompanying drawing explanation
Fig. 1 be meclofenoxate hydrochloride crystal prepared by the embodiment of the present invention 1 use the measurement of Cu-K alpha ray to obtain X-ray powder diffraction.
Detailed description of the invention
Below by specific embodiment, summary of the invention of the present invention is described in further detail, but does not therefore limit content of the present invention.
embodiment 1: the preparation of meclofenoxate hydrochloride crystal
(1) ground by meclofenoxate hydrochloride crude product, cross 80 mesh sieves, then joining volume is in the deionized water of 6 times of meclofenoxate hydrochloride weight, and 130 revs/min are stirred 10 minutes;
Add the dichloroethanes that volume is 4 times of meclofenoxate hydrochloride weight under (2) 90 revs/min of stirrings, be warming up to 35 DEG C simultaneously;
(3) after solution adds, leave standstill 3 hours, the volume dripping 0 DEG C under 150 revs/min of conditions stirred is 8 times of ether of meclofenoxate hydrochloride weight, the mixed solution of carbon tetrachloride, and the volume ratio of ether, carbon tetrachloride is 3:2, at the uniform velocity dropwises in 2 hours;
(4) be cooled to-5 DEG C after being added dropwise to complete, continue stirring 2 hours under the stir speed (S.S.) of 110 revs/min, leave standstill 1 hour crystallize out, filter, washing, vacuum drying obtains meclofenoxate hydrochloride crystal.
The X-ray powder diffraction pattern that the meclofenoxate hydrochloride crystal prepared uses the measurement of Cu-K alpha ray to obtain as shown in Figure 1.
embodiment 2: the preparation of meclofenoxate hydrochloride lyophilized injectable powder
Prescription: with parts by weight, meclofenoxate hydrochloride crystalline compounds 3 parts, trehalose 8 parts that embodiment 1 is obtained.
Preparation method: get Meclofenoxate hydrochloride compound of the present invention, inject and blunge, add the trehalose of recipe quantity, adjust ph is 4.0-5.0, be then stirred to pH constant after, mend inject water to 100 times that liquor capacity is meclofenoxate hydrochloride weight, then active carbon coarse filtration is used, successively through 1.0 μm, 0.45 μm, the microporous filter membrane aseptic filtration of 0.22 μm, filter into sterilizing room, measure pH and content qualified after, fill, pressure half plug, put into the freeze drying box being cooled to-25 DEG C, frozen drying, tamponade outlet, rolls lid.
Described lyophilization is:
Pre-freeze: by point medicinal liquid installed in-25 DEG C of insulation lyophilizing 5 hours;
Distillation: medicinal liquid good for pre-freeze is carried out evacuation ,-20 DEG C are incubated lyophilizing 15 hours;
Dry: the sample after distillation being terminated is warming up to 35 DEG C, heat preservation and dryness 3 hours.
embodiment 3: the preparation of meclofenoxate hydrochloride lyophilized injectable powder
Prescription: with parts by weight, meclofenoxate hydrochloride crystalline compounds 3 parts, trehalose 9 parts that embodiment 1 is obtained.
Preparation method: get Meclofenoxate hydrochloride compound of the present invention, inject and blunge, add the trehalose of recipe quantity, adjust ph is 4.0-5.0, be then stirred to pH constant after, mend inject water to 100 times that liquor capacity is meclofenoxate hydrochloride weight, then active carbon coarse filtration is used, successively through 1.0 μm, 0.45 μm, the microporous filter membrane aseptic filtration of 0.22 μm, filter into sterilizing room, measure pH and content qualified after, fill, pressure half plug, put into the freeze drying box being cooled to-25 DEG C, frozen drying, tamponade outlet, rolls lid.
Described lyophilization is:
Pre-freeze: by point medicinal liquid installed in-25 DEG C of insulation lyophilizing 5 hours;
Distillation: medicinal liquid good for pre-freeze is carried out evacuation ,-20 DEG C are incubated lyophilizing 15 hours;
Dry: the sample after distillation being terminated is warming up to 35 DEG C, heat preservation and dryness 3 hours.
Embodiment 4: the preparation of meclofenoxate hydrochloride lyophilized injectable powder
Prescription: with parts by weight, meclofenoxate hydrochloride crystalline compounds 3 parts, trehalose 10 parts that embodiment 1 is obtained.
Preparation method: get Meclofenoxate hydrochloride compound of the present invention, inject and blunge, add the trehalose of recipe quantity, adjust ph is 4.0-5.0, be then stirred to pH constant after, mend inject water to 100 times that liquor capacity is meclofenoxate hydrochloride weight, then active carbon coarse filtration is used, successively through 1.0 μm, 0.45 μm, the microporous filter membrane aseptic filtration of 0.22 μm, filter into sterilizing room, measure pH and content qualified after, fill, pressure half plug, put into the freeze drying box being cooled to-25 DEG C, frozen drying, tamponade outlet, rolls lid.
Described lyophilization is:
Pre-freeze: by point medicinal liquid installed in-25 DEG C of insulation lyophilizing 5 hours;
Distillation: medicinal liquid good for pre-freeze is carried out evacuation ,-20 DEG C are incubated lyophilizing 15 hours;
Dry: the sample after distillation being terminated is warming up to 35 DEG C, heat preservation and dryness 3 hours.
comparative example 1: the Meclofenoxate hydrochloride compound prepared according to patent CN103214382B embodiment 1
comparative example 2: the Meclofenoxate hydrochloride compound prepared according to patent CN103396328B embodiment 1
test example 1: hygroscopicity is investigated
This test example is respectively under the condition of humidity 80% and 90%, and each sample thief 1g is placed on electronic balance, and time recording weight, to detect moisture absorption degree, the results are shown in Table 1.
Table 1 hygroscopicity testing result
Can be found out by result of the test, compared with prior art, meclofenoxate hydrochloride crystal not easily moisture absorption prepared by the present invention, good stability.
test example 2: fluidity test
Method: sample respectively, adopt fixed funnel method, funnel is placed in the suitable height on graph paper, meclofenoxate hydrochloride is freely flowed down from bell mouth, until the cone top formed contacts with bell mouth, measure hypotenuse and the horizontal angle (θ angle of repose) of meclofenoxate hydrochloride accumulation horizon, result is as shown in table 2.
The fluidity test result of table 2 meclofenoxate hydrochloride
Can be found out by result of the test, compared with prior art, meclofenoxate hydrochloride crystal mobility prepared by the present invention is obviously improved.
test example 3: stability test
The Meclofenoxate hydrochloride compound prepare the embodiment of the present invention 1 and comparative example 1, comparative example 2 carry out accelerated stability investigation (40 DEG C ± 2 DEG C, RH75% ± 5%) by commercially available back, the results are shown in Table 3.
Table 3 Meclofenoxate hydrochloride compound accelerated test result
Can be found out by result of the test, compared with prior art, meclofenoxate hydrochloride crystal moisture prepared by the present invention obviously reduces, and always the assorted content of assorted and list is low, good stability.
24 months long term tests have been carried out to the embodiment of the present invention 1 and documents 1, documents 2, found that meclofenoxate hydrochloride crystal moisture prepared by the present invention controls within 0.06, be starkly lower than prior art, always the assorted content of assorted and list is low, good stability.
test example 4: clinical adverse monitoring test
The meclofenoxate hydrochloride provided the embodiment of the present invention 1, comparative example 1, comparative example 2 is example, carry out clinical trial, result display embodiment side reaction rate 3%, comparative example 1 side reaction rate 86%, comparative example 2 side reaction rate is 80%, show to present invention significantly reduces side reaction rate, improve the safety of clinical application.
test example 5: bioavailability study
Document " the bioequivalence Journal of Sex Research of meclofenoxate hydrochloride capsules in healthy human body " (China Dispensary the 22nd volume the 18th phase in the 2011) method of employing, by DASVer2.0 computed in software main pharmacokinetic parameters, the bioavailability of Evaluation operation example 1, comparative example 1, comparative example 2.The C of embodiment 1, comparative example 1, comparative example 2
max, AUC carries out variance analysis after Logarithm conversion, and adopts Doubled haploid population and (1-2 α) confidence interval method to evaluate further, t
maxadopt non parametric tests method.Result shows: the C of meclofenoxate hydrochloride crystal formation of the present invention
max, AUC value be better than contrast medicine 1 and contrast medicine 2 meclofenoxate hydrochloride crystal formation, the elimination half-life t of medicine of the present invention in blood plasma
l/2be greater than comparative example 1, comparative example 2.Show that meclofenoxate hydrochloride crystal formation of the present invention has better absorption characteristic and bioavailability.
Claims (8)
1. treat the medicine meclofenoxate hydrochloride composite freeze-dried powder agent of senile dementia for one kind, comprise meclofenoxate hydrochloride and excipient, it is characterized in that: described meclofenoxate hydrochloride is crystal, the X-ray powder diffraction pattern that the measurement of use Cu-K alpha ray obtains as shown in Figure 1.
2. the medicine meclofenoxate hydrochloride composite freeze-dried powder agent for the treatment of senile dementia according to claim 1, is characterized in that: with parts by weight, is made up of the meclofenoxate hydrochloride of 3 weight portions, the excipient of 8-10 weight portion.
3. the medicine meclofenoxate hydrochloride composite freeze-dried powder agent for the treatment of senile dementia according to claim 2, is characterized in that: with parts by weight, is made up of the meclofenoxate hydrochloride of 3 weight portions, the excipient of 9 weight portions.
4. the medicine meclofenoxate hydrochloride composite freeze-dried powder agent of the treatment senile dementia according to any one of claim 1-3, it is characterized in that, the preparation method of described composite freeze-dried powder agent comprises the following steps:
Get Meclofenoxate hydrochloride compound, inject and blunge, add the excipient of recipe quantity, adjust ph, be then stirred to pH constant after, mend inject water to 100 times that liquor capacity is meclofenoxate hydrochloride weight, then active carbon coarse filtration is used, successively through 1.0 μm, 0.45 μm, the microporous filter membrane aseptic filtration of 0.22 μm, filters into sterilizing room, measure pH and content qualified after, fill, pressure half plug, puts into the freeze drying box being cooled to-25 DEG C, frozen drying, tamponade outlet, rolls lid.
5., according to the medicine meclofenoxate hydrochloride composite freeze-dried powder agent of the arbitrary described treatment senile dementia of claim 1-3, it is characterized in that: described excipient is trehalose.
6. the medicine meclofenoxate hydrochloride composite freeze-dried powder agent for the treatment of senile dementia according to claim 4, it is characterized in that, described lyophilization is:
Pre-freeze: by point medicinal liquid installed in-25 DEG C of insulation lyophilizing 5 hours;
Distillation: medicinal liquid good for pre-freeze is carried out evacuation ,-20 DEG C are incubated lyophilizing 15 hours;
Dry: the sample after distillation being terminated is warming up to 35 DEG C, heat preservation and dryness 3 hours.
7. the medicine meclofenoxate hydrochloride composite freeze-dried powder agent for the treatment of senile dementia according to claim 4, is characterized in that: described adjustment pH is 4.0-5.0.
8. the medicine meclofenoxate hydrochloride composite freeze-dried powder agent for the treatment of senile dementia according to claim 1, it is characterized in that, the preparation method of the crystal of described meclofenoxate hydrochloride comprises the following steps:
(1) ground by meclofenoxate hydrochloride crude product, cross 80 mesh sieves, then joining volume is in the deionized water of 6 times of meclofenoxate hydrochloride weight, and 130 revs/min are stirred 10 minutes;
Add the dichloroethanes that volume is 4 times of meclofenoxate hydrochloride weight under (2) 90 revs/min of stirrings, be warming up to 35 DEG C simultaneously;
(3) after solution adds, leave standstill 3 hours, the volume dripping 0 DEG C under 150 revs/min of conditions stirred is 8 times of ether of meclofenoxate hydrochloride weight, the mixed solution of carbon tetrachloride, and the volume ratio of ether, carbon tetrachloride is 3:2, at the uniform velocity dropwises in 2 hours;
(4) be cooled to-5 DEG C after being added dropwise to complete, continue stirring 2 hours under the stir speed (S.S.) of 110 revs/min, leave standstill 1 hour crystallize out, filter, washing, vacuum drying obtains meclofenoxate hydrochloride crystal.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510860105.9A CN105287409A (en) | 2015-12-01 | 2015-12-01 | Medicinal meclofenoxate hydrochloride composition freeze-dried powder injection for treating senile dementia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510860105.9A CN105287409A (en) | 2015-12-01 | 2015-12-01 | Medicinal meclofenoxate hydrochloride composition freeze-dried powder injection for treating senile dementia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105287409A true CN105287409A (en) | 2016-02-03 |
Family
ID=55185708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510860105.9A Withdrawn CN105287409A (en) | 2015-12-01 | 2015-12-01 | Medicinal meclofenoxate hydrochloride composition freeze-dried powder injection for treating senile dementia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105287409A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113133975A (en) * | 2021-04-22 | 2021-07-20 | 海南通用三洋药业有限公司 | Preparation method of meclofenoxate hydrochloride freeze-dried powder injection |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6327429A (en) * | 1986-07-17 | 1988-02-05 | Ss Pharmaceut Co Ltd | Production of freeze-dried substance of meclofenoxate hydrochloride for injection |
| CN101455646A (en) * | 2009-01-06 | 2009-06-17 | 湖北德康药业有限公司 | Meclofenoxate hydrochloride preparation freeze-drying technique and preparation method thereof |
| CN103214382A (en) * | 2013-04-24 | 2013-07-24 | 四川省惠达药业有限公司 | Meclofenoxate hydrochloride compound and pharmaceutical composition thereof |
| CN103396328A (en) * | 2013-08-21 | 2013-11-20 | 湖北美林药业有限公司 | Meclofenoxate hydrochloride compound and pharmaceutical composition thereof |
-
2015
- 2015-12-01 CN CN201510860105.9A patent/CN105287409A/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6327429A (en) * | 1986-07-17 | 1988-02-05 | Ss Pharmaceut Co Ltd | Production of freeze-dried substance of meclofenoxate hydrochloride for injection |
| CN101455646A (en) * | 2009-01-06 | 2009-06-17 | 湖北德康药业有限公司 | Meclofenoxate hydrochloride preparation freeze-drying technique and preparation method thereof |
| CN103214382A (en) * | 2013-04-24 | 2013-07-24 | 四川省惠达药业有限公司 | Meclofenoxate hydrochloride compound and pharmaceutical composition thereof |
| CN103396328A (en) * | 2013-08-21 | 2013-11-20 | 湖北美林药业有限公司 | Meclofenoxate hydrochloride compound and pharmaceutical composition thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113133975A (en) * | 2021-04-22 | 2021-07-20 | 海南通用三洋药业有限公司 | Preparation method of meclofenoxate hydrochloride freeze-dried powder injection |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4187423B2 (en) | Ziprasidone composition | |
| CN105434373A (en) | Oxiracetam freeze-drying preparation for injection and preparation method thereof | |
| CN111517980A (en) | N- [8- (2-hydroxybenzoyl) amino ] caprylic acid monopotassium crystal type compound, preparation method and application | |
| CN105801568B (en) | One maleate crystal form of Afatinib and preparation method thereof and pharmaceutical composition | |
| CN106278907B (en) | A kind of Syprine Hydrochloride compound | |
| CN105287409A (en) | Medicinal meclofenoxate hydrochloride composition freeze-dried powder injection for treating senile dementia | |
| CN103214382B (en) | Meclofenoxate hydrochloride compound and pharmaceutical composition thereof | |
| CN105193819A (en) | Medicine cefotiam hydrochloride composition for treating bacterial infection | |
| CN103980279B (en) | A kind of methotrexate compound and methotrexate for injection | |
| CN105646520A (en) | Stable Halaven compound | |
| CN104844624B (en) | A kind of cefoperazone sodium sulbactam sodium eutectic and composition and method of making the same | |
| CN105287410A (en) | Medicinal meclofenoxate hydrochloride composition freeze-dried powder injection for treating traumatic coma | |
| CN105106190A (en) | Central stimulant meclofenoxate hydrochloride composition | |
| CN103450086B (en) | Ozagrel compound, preparation method and pharmaceutical composition of ozagrel compound | |
| CN105213361A (en) | A kind of medicine meclofenoxate hydrochloride compositions for the treatment of infantile enuresis | |
| CN105343046A (en) | Brain neurotrophic drug meclofenoxate hydrochloride composition | |
| CN104829467A (en) | Ambroxol hydrochloride dihydrate compound | |
| CN105106189A (en) | Meclofenoxate hydrochloride pharmaceutical composition capable of promoting brain energy metabolism | |
| CN104761463B (en) | D pantothenic acid sodium crystal and its production and use | |
| CN105130828A (en) | Drug meclofenoxate hydrochloride compound for adjusting nerve cell metabolism | |
| CN102827147A (en) | Omeprazole sodium crystal compound and medicine composition containing omeprazole sodium crystal compound | |
| CN102408375A (en) | Ozagrel sodium compound | |
| CN103724359B (en) | A kind of amorphous cefotetan acid and prepared the method for Cefotetan Disodium and containing the pharmaceutical composition of this Cefotetan Disodium by it | |
| CN104860839B (en) | Aceglutamide crystal and preparation | |
| CN105541946A (en) | Adenosine cyclophosphate crystalline compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160203 |
|
| WW01 | Invention patent application withdrawn after publication |